Clinical trialNCT04858256RecruitingPhase 2Interventional

Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms

SponsorUniversity of Michigan Rogel Cancer CenterEnrollment100Lymphoproliferative DisordersT-Cell Neoplasm

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The main purpose of this study is to determine the effectiveness of the study drug pacritinib in people with relapsed or refractory lymphoproliferative disorders.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Ryan Wilcox, MD, PhD
University of Michigan Rogel Cancer Center
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

City of Hope
Duarte, California, United States
Christina Poh, MD
Recruiting
Moffitt Cancer Center
Tampa, Florida, United States
Lubomir Sokol
Not, yet, recruiting
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, United States
Ryan Wilcox, MD, PhD
Recruiting
Duke Cancer Institute
Durham, North Carolina, United States
Jie Wang →
Recruiting
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
John Reneau
Recruiting
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
Natalie Galanina
Not, yet, recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Pacritinib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 29 Mar 2023
Primary completion: 30 Nov 2027
Completion: 30 Nov 2028
Last update posted: 29 Jan 2026
Registered enrollment: 100
Registry id: NCT04858256

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.